advertisement

---

Wolf AT 10

Showing records 1 to 10 | Display all abstracts from Wolf AT

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Wolf AT; Wolf AT
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Shin JD
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Harris A
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Wolf AT; Wolf AT; Harris A
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Oddone F
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Verticchio Vercellin A
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Siesky B
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Siesky B
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Verticchio Vercellin A; Ciulla TA
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Rowe LW; Rowe LW; Packles M; Oddone F
Acta Ophthalmologica 2022; 100: e377-e385

---